MedTrace Logo

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2020-09-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of PF 03187207.

Conditions

  • Primary Open Angle Glaucoma
  • Ocular Hypertension
  • Pigmentary Glaucoma
  • Pseudoexfoliative Glaucoma

Interventions

DRUG

PF-03187207 and Latanoprost Vehicle

DRUG

Latanoprost 0.005% and PF-03187207 Vehicle

Sponsors & Collaborators

  • NicOx Inc.

    collaborator INDUSTRY

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Principal Investigators

  • Kenneth Harper · Bausch & Lomb Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-02-29
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441883 on ClinicalTrials.gov